Lucintel Profiles Top Five Global Cardiovascular Drugs Companies

Share Article

Lucintel Profiles Top Five Global Cardiovascular Drugs Companies

Insights that Matter

Insights that Matter

The global cardiovascular drugs industry experienced average growth over the last five years and is expected to reach approximately US $174.8 billion in 2017, growing with a CAGR of 2.9% over the next five years. Top companies are making strategic acquisitions both to expand their global footprints and to take advantage of established business and expertise gained from acquired companies.

Lucintel, a leading global management consulting and market research firm, has conducted a competitive analysis of the leading global cardiovascular drugs companies and presents its findings in “Top Five Global Cardiovascular Drugs Companies Performance, Strategies, and Competitive Analysis.” The report provides detailed insights into the performance of the top five companies across the world. The analysis highlights the companies that are performing the best among the peer group, and in which areas, and therefore clarifies leading performance standards and the strengths and weaknesses of companies covered.

The global cardiovascular drugs industry is consolidated with all classes of drugs used for the treatment of cardiovascular diseases such as hypertension, high cholesterol, heart failure, acute stroke, abnormal rhythms of the heart, chest pain, and other cardiac disorders. The industry is dominated by the North America region. In this study, Lucintel thoroughly profiles the following five companies with detailed competitive assessments:

  •     AstraZeneca            
  •     Bristol-Myers Squibb
  •     Novartis        
  •     Pfizer            
  •     Sanofi         

As indicted in the study, the thrombotic drugs segment is currently small, but holds great growth potential in the future. The launch and development of new products, incorporated with innovative technologies, will drive the growth as manufacturers look for ways to differentiate themselves from their competitors.

This medical market report is intended to provide industry leaders with a competitive benchmarking of the world’s top five cardiovascular drugs companies. The study provides up-to-date information on the market share, profit margins, capabilities, and strategies of the leaders. It is designed to provide executives with strategically significant competitor information, data analysis and M & A due diligence, insight, critical to the development and implementation of an effective marketing and sales plan.

For a detailed table of contents and pricing information on this timely, insightful report, contact Lucintel at +1-972-636-5056 or via email at helpdesk(at)lucintel(dot)com. Lucintel provides cutting-edge decision support services that facilitate critical decisions with greater speed, insight, and cost efficiency. To learn more, visit http://www.lucintel.com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Joseph E. Fritz
Lucintel
+1-972-636-5056
Email >
Visit website